Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials

Published on: Thursday, September 20th, 2018 View all Media

RUTHERFORD, N.J., Sept. 20, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the successful CLIA validation and commercial launch of Thermo Fisher Scientific’s next-generation sequencing (NGS) Oncomine™ Comprehensive Assay v3 for biopharma clinical trials.

John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “As we have previously announced, we are continuing to gain momentum with key channel partners. Oncomine™ Comprehensive Assay v3 provides confidence in understanding cancer mutations. This newest version of the assay supports both translational and clinical researchers with superior tumor profiling capabilities that enable reliable results. We are excited about the potential of the Oncomine Comprehensive Assay in drastically improving clinical oncology research.”

Oncomine Comprehensive Assay v3 features content based on the advances in clinical oncology research. It enables simultaneous analysis of DNA and RNA to detect hundreds of variant types, including single nucleotide variants (SNVs), copy number variations (CNVs), gene fusions, and indels from unique cancer driver genes, across 161 genes relevant to solid tumors.

It also covers the entire kinase domain in several critical receptor tyrosine kinases, which increases the likelihood of detecting functionally relevant mutations in addition to known actionable and prevalent variants. Additionally, the assay represents 31 genes involved in the DNA repair pathway and covers MAPK, PI3K, and cell cycle pathway genes.

Oncomine™ Comprehensive Assay v3 requires only 10 ng of DNA or RNA per pool to deliver analysis of even small and challenging formalin-fixed, paraffin-embedded (FFPE) samples. It is optimized for automated library preparation using the Ion Chef System and rapid sequencing on the Ion GeneStudio S5 Systems with analysis reporting using the Oncomine™ Knowledgebase Reporter, which aligns results with the most recent published evidence on clinical oncology research.


ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, Australia and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

 

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2017 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.